Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Core Insights - Werewolf Therapeutics, Inc. has appointed Steven Bloom as Chief Business Officer, bringing over 35 years of experience in the life sciences industry [1][2] - The company is at a pivotal moment with upcoming interim dose expansion data from the WTX-124 Phase 1/1b clinical trial, which is expected to inform regulatory discussions on potential registrational pathways [2] - Werewolf is advancing its PREDATOR platform to develop novel molecules for oncology and immunology, with a focus on minimizing patient side effects while effectively targeting tumors [3] Company Overview - Werewolf Therapeutics is focused on developing conditionally activated therapeutics that stimulate the immune system for cancer and other immune-mediated conditions [5] - The company utilizes its proprietary PREDATOR platform to create INDUKINE molecules that activate selectively in the tumor microenvironment, aiming to overcome limitations of traditional immune therapies [5] - The lead product candidates, WTX-124 and WTX-330, are designed for the treatment of solid tumors and Non-Hodgkin Lymphoma, respectively [5] Leadership Background - Steven Bloom previously served as Chief Business Officer at Vincerx Pharma, where he led business development and corporate strategy initiatives [2] - His experience includes senior roles at various biotechnology companies and Eli Lilly, focusing on sales, marketing, and corporate affairs [2][3] - Bloom is also involved in community service as Chair of the Board of Directors of the CLL Society, which supports chronic lymphocytic leukemia patients [3] Stock Option Grant - In connection with Bloom's appointment, Werewolf's board approved a stock option grant allowing him to purchase up to 201,720 shares of common stock at the closing price on May 1, 2025 [4] - The stock option has a ten-year term, with 25% vesting on the first anniversary of his employment and the remaining 75% vesting in 36 equal monthly installments [4]